Both account & customer growth seems to have slowed, although class portfolio seems to gaining traction (I imagine with existing clients). Not sure that the market will like this given the high PE
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025